PSMA, a type 2 transmembrane glycoprotein, is known to be overexpressed in prostate tumours [3,4], and its level of expression correlates with high serum levels of prostate-specific antigen (PSA) and a higher Gleason score. The gene discussed is KLK3; the disease is prostate neoplasm.